• Incidence of serious adverse drug reactions, evaluated via number of major hypoglycaemic events [ Time Frame: For the duration of the study (32 weeks) ] [ Designated as safety issue: Yes ]
  

• Number of serious adverse events [ Time Frame: For the duration of the study ] [ Designated as safety issue: Yes ]
  
• Number of all adverse events [ Time Frame: For the duration of the study ] [ Designated as safety issue: Yes ]
  
• Number of all - daytime and nocturnal - hypoglycaemic events [ Time Frame: In the 4 weeks before baseline compared to 4 weeks before interim and final visits ] [ Designated as safety issue: Yes ]
  
• Weight changes compared to baseline [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
  
• HbA1c compared to baseline [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
  
• Fasting glucose level control compared to baseline as measured by FBG [ Time Frame: After 16 and 32 weeks of treatment ] [ Designated as safety issue: No ]
  

Type 2 diabetic patients

Inclusion Criteria:

• After the physician decision has been made to use insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician

Exclusion Criteria:

• Subjects who are unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for the final visit;
• Subjects currently being treated with insulin detemir;
• Subjects who previously enrolled in this study or studies related to NovoMix 30;
• Subjects with a hypersensitivity to insulin detemir or to any of the excipients;
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 8 months.